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Histone deacetylase (HDAC) inhibitors represent a potential new class of antitumor agents. Vorinostat (suberoylanilide hydroxamic
acid or SAHA) is a potent inhibitor of HDAC activity and has undergone initial evaluation in several Phase I and II clinical trials.
HDACs are enzymes that catalyse the removal of the acetyl moiety from the lysine residues of proteins, including the core
nucleosomal histones. Together with histone acetyltransferases (HATs), HDACs regulate the level of protein acetylation. Alterations
in both HAT and HDAC activity have been reported to occur in cancer. HAT activity has been found to be disrupted by
translocation, amplification, overexpression or mutation in a variety of cancers, including those of haematological or epithelial origin.
HDACs have been found to be overexpressed or associated with oncogenic transcription factors. Vorinostat induces growth arrest,
differentiation or apoptosis in a variety of transformed cells. The antiproliferative effects of vorinostat are believed to be due to drug-
induced accumulation of acetylated proteins, including the core nucleosomal histones and other proteins (e.g., BCL6, p53 and
Hsp90). Phase I and II trials have been conducted for the oral formulations of vorinostat, and results show that vorinostat inhibits its
target enzyme (HDAC) in peripheral mononuclear cells and tumour tissue at doses that are well tolerated. Antitumour activity has
been seen in patients with both haematological and solid tumours.
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Although a key characteristic of neoplastic transformation is
unregulated cellular proliferation, cancer cells nevertheless retain
their ability to undergo differentiation or apoptosis under certain
circumstances (Marks et al, 2001). Research efforts have been
focused on attempting to exploit this characteristic of tumour cells
by identifying new anticancer therapies capable of triggering
growth arrest, differentiation and/or apoptosis of transformed
cells. In this regard, a new class of antitumour agents – histone
deacetylase (HDAC) inhibitors – has received particular attention.
The HDAC inhibitor vorinostat (suberoylanilide hydroxamic
acid or SAHA) blocks cancer cell proliferation both in vitro
and in vivo with little or no toxicity to normal cells and has
undergone evaluation in several Phase I and II clinical trials (Kelly
et al, 2003, 2005; Duvic et al, 2005). This review discusses the
effects of HDAC in modulating gene expression via histone
acetylation and the role of abnormal HDAC activity in cancer
development, summarises the wealth of in vitro and in vivo data
demonstrating the antitumour effects of vorinostat, and explores
current hypotheses on the potential mechanism(s) of action of
vorinostat that may contribute to its antitumour activity.
ROLE OF HDAC IN REGULATING GENE EXPRESSION
AND CANCER DEVELOPMENT
Nucleosomes comprise the repeating unit of chromatin and serve
to organise and compress the DNA in the nucleus. They are
composed of the octamer of core histones (two molecules each of
histones H2A, H2B, H3 and H4) spanning approximately 200bp of
DNA. The acetylation status of histones plays an important role in
regulating gene expression by altering the structure of chromatin
(Grunstein, 1997; Gregory et al, 2001). Regulation of histone
acetylation is controlled by two enzyme families: histone
acetyltransferases (HAT), which catalyses the addition of acetyl
moieties to lysine residues of proteins, and histone deacetylases
(HDAC), which catalyses their removal. HAT promotes gene
transcription by acetylating histones, thereby facilitating an open
chromatin structure. In contrast, HDACs deacetylate histones
thereby facilitating a closed chromatin structure and hence
transcriptional repression. Specifically, HDACs are believed to
remove an acetyl group from the e-amino group of the lysine side
chain of histones H2A, H2B, H3 and H4, thereby reconstituting the
positive charge on the lysine residues.
Three classes of HDAC have so far been identified: Classes I, II
and III (for detailed review see Marks and Dokmanovic, 2005 and
Verdin et al, 2003). The catalytic domain of Class I and II HDACs
is NAD-independent and zinc-dependent, whereas the domain of
Class III is NAD-dependent and zinc-independent. To date, a total
of 11 Classes I and II human HDACs have been described, which
are categorised according to the homology of their catalytic
domain and structure (Figure 1). Class IIA enzymes have a long
amino terminus and IIB enzymes have two catalytic domains. The
different HDACs form large multiprotein complexes, including for
example MTA2, Mi-2 and SMRT/N-CoR.
Alterations in the enzymes modifying histone acetylation are
important from a cancer biology perspective in that HDAC is *Correspondence: Dr VM Richon; E-mail: victoria_richon@merck.com
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oncogenic transcription factors. For example, HDAC appears to be
overexpressed in gastric (Song et al, 2005), prostate (Halkidou
et al, 2004), and colon cancer (Zhu et al, 2004) and aberrant HDAC
activity may also occur in certain forms of leukaemia (Fenrick and
Hiebert, 1998) and lymphoma (Table 1) ([Lemercier et al, 2002). In
acute promyelocytic leukaemia, for example, the transcriptional
activator retinoic acid receptor alpha (RARa) is fused with the
promyelocytic leukaemia (PML) gene on chromosome 15 forming a
complex (PML-RARa) that results in HDAC recruitment and
transcriptional repression (Grignani et al, 1998; He et al, 1998).
Genes that encode HAT can also be translocated, amplified,
overexpressed and/or mutated in various cancers, including
haematological and epithelial malignancies (Table 1). One model
of cancer formation, therefore, is the generation of deacetylated
proteins due to the overactivity of HDAC or the inactivation of HAT.
VORINOSTAT – A POTENT INHIBITOR OF HDAC
ACTIVITY
Vorinostat (suberoylanilide hydroxamic acid or SAHA) is a
nanomolar inhibitor of HDAC activity that has undergone initial
evaluation in multiple Phase I and II clinical trials. Vorinostat is a
small molecular weight (o300) linear hydroxamic acid compound
that inhibits HDAC activity thereby inducing the accumulation
of acetylated histones as well as nonhistone proteins, blocks the
proliferation of cultured cells, and inhibits tumour growth in a
variety of animal models. Vorinostat is a broad inhibitor of HDAC
activity and inhibits both classes I and II enzymes (Marks et al,
2001;Marks and Dokmanovic, 2005). As with other HDAC
inhibitors in clinical development, vorinostat does not inhibit
HDACs belonging to Class III.
Crystallographic studies have revealed that vorinostat inhibits
HDAC activity by binding in the active site of the enzyme (Finnin
et al, 1999). As shown in the molecular netting diagram (Figure 2),
the hydroxamic end of the molecule binding to the zinc atom in
the HDAC catalytic site, with the phenyl ring of vorinostat
projecting out of the catalytic pocket on to the surface of HDAC.
IN VITRO ANTITUMOR ACTIVITY OF VORINOSTAT
Vorinostat has been shown to inhibit the proliferation of a wide
variety of transformed cells in vitro, including lymphoma,
myeloma, leukaemia, and non-small cell lung carcinoma with
concentrations that inhibit growth by 50% compared to no
treatment ranging from approximately 0.5 to 10mM (Table 2)
(Kelly et al, 2005). The inhibitory effects of vorinostat on cell
proliferation tended to vary across multiple cell lines of a
particular tumour type. This variability is illustrated by the recent
findings from Koeffler and co-workers showing that vorinostat
produced a profound but variable degree of inhibition of
proliferation of lymphoma and leukaemia cells, including Burkitt,
B-cell acute lymphoblastic leukaemia (B-ALL), MCL, DLBCL, ATL
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Figure 1 Classes I and II human HDACs categorised according to the
homology of their catalytic domain and structure.
Table 1 Summary of acetylation defects observed in various cancers
Leukemia HAT fusions HDAC mediated
MOZ/CBP PML/RARalpha
MOZ/p300 PLZF/RARalpha
MOZ/TIF-2 AML1 fusion
MLL/CBP
MLL/p300
Lymphoma BCL6
STAT5
Epithelial cancers p300 mutations in colorectal, gastric, breast,
pancreatic carcinomas/cancer cell lines
Gastric cancer Elevated expression of HDAC1
Prostate cancer Elevated expression of HDAC1
Colon cancer Elevated expression of HDAC1 and HDAC2
Vorinostat (suberoylanilide hydroxamic acid, SAHA)
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Figure 2 Vorinostat inhibits HDAC activity by binding to the pocket of
the catalytic site. The hydroxamic acid moiety of vorinostat binds to a zinc
atom (pink), allowing the rest of the molecule to lie along the surface of the
HDLP protein (Marks et al, 2001).
Table 2 Vorinostat inhibits proliferation of a variety of transformed cells
in vitro
Lymphoma Breast adenocarcinoma
Myeloma Pancreatic cancer
Leukaemia Glioblastoma
Mesothelioma Prostate cancer
Non-small cell lung carcinoma Ovarian cancer
Bladder carcinoma Melanoma
Colon carcinoma Renal cell carcinoma
Thyroid cancer Endometrial cancer
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the ED50 for inhibition of cellular proliferation was 0.83mM for the
SUDHL6 cell line and 1.9mM for the SUDHL16 cell line.
In addition to inhibiting the proliferation of transformed cells,
vorinostat also inhibits proliferation of normal cells, as evidenced
by comparing the effects of vorinostat on a matched panel of cells
lines – normal human lung fibroblast cells (WI-38) and SV40
large T antigen transformed WI-38 (VA-13 cells) (Ungerstedt et al,
2005). Vorinostat resulted in a dose-dependent inhibition of
proliferation of both cell types but was found to be selectively toxic
to transformed cells, inducing death in tumour cells but leaving
normal cells growth-inhibited but viable (Marks et al, 2001). The
reason for this selective toxicity is incompletely understood,
however, these studies provide evidence for an important role of
thioredoxin in mediating the resistance of normal cells to
vorinostat-induced cell death.
IN VIVO ANTITUMOUR ACTIVITY OF VORINOSTAT
Vorinostat inhibits tumour growth in rodent models of a variety of
solid tumours and haematological malignancies by both parenteral
and oral administration (Table 3), including prostate cancer,
(Butler et al, 2000) leukaemia (He et al, 2001), breast cancer
(Cohen et al, 1999;Cohen et al, 2002), glioma (Eyupoglu et al, 2005)
and lung cancer (Desai et al, 2003). Inhibition of tumour growth
occurs at vorinostat doses that have little or no toxicity, as
evaluated by weight gain, histological studies and gross anatomic
examination of tissues/organs at autopsy (Butler et al, 2000).
Vorinostat administered in the diet has been shown to inhibit the
development of rat mammary tumours induced by the carcinogen
N-methylnitrosourea (Cohen et al, 1999). Administration of
vorinostat decreased tumour incidence and inhibited the growth
of established mammary tumours (Cohen et al, 2002).
Vorinostat has also been shown to suppress growth of a trans-
planted androgen-dependent human prostate tumour (CWR222)
in nude mice (Butler et al, 2000). At a dose of 50mgkg
1day
1,
vorinostat decreased the mean final tumour volume by 97%
compared with controls without detectable toxicity. Within 6h of
vorinostat administration, an increase in the accumulation of
acetylated core histones was detected in CWR22 tumours.
On the basis of these and other studies, vorinostat has
undergone evaluation in Phase I and II clinical trials in patients
with solid tumours and haematological malignancies, including
cutaneous T-cell lymphoma (Kelly et al, 2005, 2003; Duvic et al,
2005). These clinical studies are reviewed in detail in other articles
comprising this supplement.
MECHANISM OF ACTION OF VORINOSTAT
The mechanism for the antiproliferative effect of vorinostat is
believed to be the result of inhibition of HDAC activity, resulting in
the accumulation of acetylated proteins, including histones.
Inhibition of HDAC activity by vorinostat has multiple cellular
effects (Johnstone and Licht, 2003; Secrist et al, 2003). These effects
include an alteration in the transcription of a finite number of
genes (2–5% of expressed genes) via acetylation of histones and
transcription factors, as well as nontranscriptional effects such as
cell cycle arrest via inhibition of mitosis (Figure 3) (Marks et al,
2004). Vorinostat has been shown to impact the expression
of several genes, some of which are induced (p21
WAF1, TBP-2,
gelsolin, metallothionein 1L, histone H2B) while others are
repressed (cyclin D1, ErbB2, thymidylate synthase, importin b)
(Glaser et al, 2003). Induction of gene expression for the cell kinase
inhibitor p21
WAF1 has been shown for several HDAC inhibitors
including vorinostat and this effect may play a critical role in the
growth arrest of transformed cells (Richon et al, 2000). Vorinostat
induces up to a nine-fold increase in p21
WAF1 mRNA and protein
in T24 bladder carcinoma cells (Richon et al, 2000). This
effect appears to be due in part to an increase in the rate of gene
transcription associated with acetylation of the histones H3 and
H4 associated with the p21
WAF1 promoter (Richon et al, 2000;
Gui et al, 2004).
Vorinostat may also promote the acetylation of numerous
transcription factors, including androgen receptor, E2F-1, YY1,
Smad7, EKLF, p53, BCL-6, HIF-1, NF-Y, NF-kappaB and GATA-1
Table 3 Parenteral or oral administration of vorinostat inhibits growth of
a variety of tumours in rodents
Parenteral administration Oral administration
Prostate cancer (CWR22 xenograft) Breast adenocarcinoma
(N-methylnitrosourea-induced)
Leukaemia (acute promyelocytic leukaemia
transgenic)
Lung tumours (tobacco-specific
nitrosamine-induced)
Lymphoma (mantle cell, Em-myc transgenic)
Glioma (F98 cells)
Vorinostat
HDAC
Histone acetylation Protein acetylation
Ac Ac Ac Ac Ac Ac Ac Ac Ac
Ac Ac Ac Ac Ac Ac
Ac
Ac
Ac Ac
Ac Ac
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Hsp90
Cell cycle arrest and apoptosis
Anthracycline
Radiation
Cisplatin
Decitabine
Targretin
Taxanes
l
↓ ↓ raf-1
↓ ErbB1
↓ ErbB2
17-AAG
Trastuzumab
↑ p21WAF1
↓ TS
↓ VEGF
↓ STAT5 genes
↑ p53 genes
↑ BCL6 genes
5-FU
Flavopiridol
Bevacizumab
Figure 3 Proposed mechanisms of action of vorinostat in inducing tumor cell cycle arrest and apoptosis.
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transcription factor acetylation may result in an alteration in the
expression of certain genes. For example, acetylation of the p53
transcriptional activator leads to increased binding of p53 to DNA,
which in turn, increases the expression of p53-regulated genes.
Patients with lymphoma show increased activity of the trans-
criptional repressor BCL6, and acetylation of BCL6 can give rise to
an inhibition of transcriptional repression by BCL6 (Bereshchenko
et al, 2002).
In addition to histones and transcription factors, HDAC
inhibitors have also been shown to acetylate the lysine residues
of a number of proteins, including a-tubulin and the heat-shock
protein Hsp90. Inhibition of HDAC6 activity leads to acetylation
and disruption of Hsp90 and this, in turn, may lead to decreases in
activity of progrowth and prosurvival client proteins, such as
Bcr-Abl, mutant FLT-3, c-Raf and AKT in human leukaemia cells
(Bali et al, 2005).
Evidence also exists that HDAC inhibitors influence the ability
of tumour cells to undergo mitosis (Secrist et al, 2003). By causing
an increase in acetylated histones and other proteins, HDAC
inhibitors may disrupt the cell cycle and induce apoptosis
of tumour cells by targeting cell cycle checkpoint controls – a G2
check point, which is often defective in tumour cells, and a mitotic
spindle check point (Warrener et al, 2003). In vitro studies indicate
that HDAC inhibitors give rise to aberrant spindles most likely
by interfering with chromosome attachment, thereby producing
mitotic accumulation without affecting mitotic microtubules
(Sandor et al, 2000).
Further research into the mechanism(s) of action of vorinostat
as well as delineation of its clinical utility in various cancer
types should help formulate rational combinations with other
chemotherapeutic agents that may provide synergistic or additive
antitumour efficacy. Based on a mechanistic rationale, vorinostat
has the potential to be combined with several different types of
anticancer therapies, including radiation, anthracyclines, cisplatin,
taxanes, 5-fluorouracil (5-FU), flavopiridol, bevacizumab and
trastuzumab (Figure 3). Preliminary studies of tumour cells in
culture suggest that vorinostat may be additive and even
synergistic with radiation therapy and selected chemotherapeutic
agents in inhibiting proliferation or inducing apoptosis (Table 4).
SUMMARY
Vorinostat, a potent inhibitor of Classes I and II HDAC activity with
an IC50 o86nM, induces histone and protein acetylation and alters
gene expression. Vorinostat blocks growth promoting signal
transduction pathways and the proliferation of a broad spectrum
of cultured cancer cells. Parenteral and oral administration of
vorinostat at doses producing little or no toxicity to normal cells
results in growth arrest in rodent models of several solid tumours
and haematological malignancies, including prostate cancer, leu-
kaemia, breast cancer, colon cancer and lung cancer. The
mechanism underlying the antitumour action of vorinostat is not
yet clear but may involve changes in the expression of specific genes
via acetylation of histones and transcription factors as well as
nontranscriptional effects such as inhibition of mitosis. Further
research to delineate the mechanism(s) of action of vorinostat and
other HDAC inhibitors may pave the way to developing rational
combinations with other chemotherapeutic agents and perhaps
ultimately to optimising chemotherapy regimens for cancer patients.
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